Trimetazidine is an effective antianginal drug that with its minimal side effect profile it has an important role to play when side effects limit haemodynamic agents and in those vulnerable to adverse effects such as one elderly – highlighted in a study conducted by Graham Jackson, Guy’s & St Thomas’ Hospital, Cardiothoracic Centre, St Thomas? Hospital, London, UK
Trimetazidine, a metabolic agent, acts at the cellular level to improve myocardial metabolism at the time of ischemia. A recent Cochrane Collaboration review of its use in stable angina has confirmed its effectiveness in reducing anginal attacks and nitrate consumption, at the same time as improving exercise performance with minimal adverse events. Additional reports identifying improved left ventricular function in cardiac failure suggest a potential prognostic role.